ethyl 2-(2-methoxyphenyl)acetimidate hydrochloride | 142682-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 2-(2-methoxyphenyl)acetimidate hydrochloride
• 英文别名: ethyl(2-methoxyphenyl)acetoimidate hydrochloride；ethyl 2-(2-methoxyphenyl)acetimidate monohydrochloride；[1-Ethoxy-2-(2-methoxyphenyl)ethylidene]azanium;chloride；[1-ethoxy-2-(2-methoxyphenyl)ethylidene]azanium;chloride
• CAS: 142682-69-7
• 化学式: C₁₁H₁₅NO₂*ClH
• 分子量: 229.707
• InChiKey: RIWULEHPCFUINV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.67
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  42.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-methoxyphenyl)acetimidate hydrochloride 在 盐酸 、 水 、 碳酸氢钠 作用下， 以 乙醚 为溶剂， 90.0 ℃ 、101.33 kPa 条件下， 反应 20.5h， 生成 乙基(2-甲氧基苯基)(氧代)乙酸酯
  参考文献：
  名称：

  铜（II）催化的（杂）芳基乙酰乙酸苯甲酸C（sp 3）–H有氧氧化：芳基-α-酮酸酯的合成

  摘要：

  本文开发了一种简单的方法，使用分子氧作为可持续的氧化剂，通过铜催化的（杂）芳基乙酰亚氨酸的需氧氧化，合成α-酮酸酯。该反应代表了通过对苄基C （sp3） -H（C═O）键进行有氧氧化以中等至良好收率，由芳基乙酰亚氨酸酯直接合成芳基-α-酮酸酯的第一个例子。这种转化在温和的反应条件下与多种底物一起发生，并利用了容易获得的氧化剂和催化剂。这种转化的合成效用通过放大合成得到了证明。还提出了合理的反应机理。

  DOI：

  10.1021/acs.joc.6b02176
• 作为产物：
  描述：

  乙醇 、 邻甲氧基苯乙腈 在 乙酰氯 作用下， 以86%的产率得到ethyl 2-(2-methoxyphenyl)acetimidate hydrochloride
  参考文献：
  名称：

  铜（II）介导的苯甲酰亚胺酯的有氧氧化：初级α-酮酰胺的合成

  摘要：

  已经发现一种简单直接的合成伯α-酮酰胺的方法。该反应代表了通过使用可持续的分子氧作为氧化剂将亚氨基苄基酯直接转化为伯α-酮酰胺的第一个例子。该反应在铜盐（II）的存在下通过裂解亚氨酸苄基的苄基C–H和C–O键进行，唯一的副产物是醇的释放。广泛的底物范围，操作温和的条件，使用单个底物以及放大至克数的反应，使得该策略非常具有吸引力和实用性。此外，机理研究表明，与苄基位置相邻的亚氨酸酯基团在促进该化学过程中起着至关重要的作用。

  DOI：

  10.1021/acs.joc.6b01262

文献信息

• [EN] PYRIMIDINE INHIBITORS OF KINASE ACTIVITY<br/>[FR] INHIBITEURS PYRIMIDINES DE L'ACTIVITÉ KINASE
  申请人：ABBOTT LAB

  公开号：WO2010138575A1

  公开（公告）日：2010-12-02

  Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

  本文描述了式（I）的化合物或其药用可接受的盐或溶剂化合物，其中G1、L1、R2、R3、n、p、Ar1和Ar2在描述中有定义。还公开了制备所述化合物的方法，以及包含所述化合物的用于抑制IGF-IR等激酶的组合物。
• Heterocyclic compounds
  申请人：Yamada Tatsuhiro

  公开号：US20050250796A1

  公开（公告）日：2005-11-10

  The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Y 1 and Y 2 are nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

  这项创新主题涉及包含由式（I）表示的杂环化合物的化合物、药物组合物和试剂盒，其中R是一个烷基基团，可选择地具有取代基等，X是一个氨基基团，可选择地具有取代基等，Y1和Y2是氮原子等，其异构体或溶剂化合物或其药用可接受盐作为活性成分。
• Nitrogeneous cyclic ketone derivative, process for producing the same, and use
  申请人：Yamaoka Masayoshi

  公开号：US20050038072A1

  公开（公告）日：2005-02-17

  A novel compound represented by the formula (I): wherein rings A and B each represents an optionally substituted aromatic ring, or rings A and B may be bonded to each other through linking between bonds or substituents thereof to form a ring; ring C represents a nitrogenous saturated heterocycle optionally having one or more substituents besides the oxo (provided that 2,3-dioxopyrrolidine ring is excluded); R 1 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and indicates a single bond or a double bond. It has high antagonistic activity against a tachykinin receptor, especially an SP receptor.

  一种新的化合物，化学式表示为（I）：其中环A和环B分别代表一个可选取代芳香环，或者环A和环B通过键或它们的取代基之间的连接结合形成一个环；环C代表一个氮饱和杂环，除了氧代（提供2,3-二氧代吡咯烷环除外）之外，还可以选择具有一个或多个取代基；R1代表氢、可选取代的碳氢基团或可选取代的杂环基团；表示单键或双键。它对一种快速激动肽受体，尤其是SP受体具有高拮抗活性。
• NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1460062A1

  公开（公告）日：2004-09-22

  A novel compound represented by the formula (I): wherein rings A and B each represents an optionally substituted aromatic ring, or rings A and B may be bonded to each other through linking between bonds or substituents thereof to form a ring; ring C represents a nitrogenous saturated heterocycle optionally having one or more substituents besides the oxo (provided that 2,3-dioxopyrrolidine ring is excluded); R1 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and --------¯ indicates a single bond or a double bond. It has high antagonistic activity against a tachykinin receptor, especially an SP receptor.

  一种由式(I)代表的新型化合物： 其中，环 A 和环 B 各自代表一个任选取代的芳香环，或环 A 和环 B 可通过其键或取代基之间的连接而相互键合，形成一个环；环 C 代表一个含氮饱和杂环，除了氧代外，还可任选具有一个或多个取代基（前提是不包括 2,3-二氧代吡咯烷环）；R1 代表氢、任选取代的烃基或任选取代的杂环基；以及 --------¯ 表示单键或双键。它对速激肽受体，尤其是 SP 受体具有很高的拮抗活性。
• 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies
  作者：Lucia Squarcialupi、Vittoria Colotta、Daniela Catarzi、Flavia Varano、Marco Betti、Katia Varani、Fabrizio Vincenzi、Pier Andrea Borea、Nicola Porta、Antonella Ciancetta、Stefano Moro

  DOI：10.1016/j.ejmech.2014.07.060

  日期：2014.9

  In previous research, several 7-amino-2-arylpyrazolo[4,3-d]pyrimidine derivatives were identified as highly potent and selective antagonists at the human A3 adenosine receptor. Structure-activity relationship studies highlighted that affinity and selectivity depended on the nature of the substituents at the 5- and 7-positions of the pyrazolo[4,3-d]pyrimidine scaffold. In particular, small lipophilic residues at the 5-position and a free amino group at position 7 afforded compounds able to bind all four human (h) adenosine receptors. Hence, to shift affinity toward the hA1 and/or hA(2A) subtypes, alkyl and arylalkyl chains of different length were appended at position 5 of the 2-phenylpyrazolo[4,3-d]pyrimidin-7-amine. Among the new compounds, a dual hA1/hA(2A) receptor antagonist was identified, namely the 5-(3-phenylpropyl) derivative 25, which shows high affinity both at human A1 (K(i) = 5.31 nM) and A(2A) (K(i) = 55 nM) receptors. We also obtained some potent and selective antagonists for the A1 receptor, such as the 5-(3-arylpropyl)-substituted compounds 26-31, whose affinities fall in the low nanomolar range (K(i) = 0.15-18 nM). Through an in silico receptor-driven approach, the obtained binding data were rationalized and the molecular bases of the hA1 and hA(2A) AR affinity and selectivity of derivatives 25-31 are explained.